Thienyl-, furyl-, pyrrolyl- and phenylsulfonamides, formulations of pharmaceutically-acceptable derivatives thereof and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides, N-(isoxazolyl)pyrrolylsulfonamides and N-(isoxazolyl)phenylsulfonamides, formulations thereof and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or pharmaceutically acceptable derivatives thereof that inhibit the activity of endothelin are also provided.

Thienyl -, furyl -, o pyrrolyl- e os phenylsulfonamides, os formulations de derivatives pharmaceutically-acceptable disso e os métodos para modular ou alterar a atividade da família do endothelin dos peptides são fornecidos. No detalhe, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides, N-(isoxazolyl)pyrrolylsulfonamides e N-(isoxazolyl)phenylsulfonamides, os formulations disso e os métodos que usam estes sulfonamides para inibir o emperramento de um peptide do endothelin a um receptor do endothelin contatando o receptor com o sulfonamide são fornecidos. Os métodos para tratar disorders endothelin-mediados administrando quantidades eficazes de uma ou mais destes sulfonamides ou os derivatives aceitáveis que inibem a atividade do endothelin são fornecidos pharmaceutically disso também.